{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:39:41Z","timestamp":1789011581502,"version":"build-2803163510"},"reference-count":15,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Vaccinations are effective in preventing infections; however, it is unknown if patients with chronic lymphocytic leukemia (CLL) who are treatment na\u00efve (TN) or receiving Bruton tyrosine kinase inhibitors (BTKi's) respond to novel adjuvanted vaccines. Understanding the effect of BTKi's on humoral immunity is timely because BTKi's are widely used and vaccination against coronavirus disease 2019 is urgently needed. In 2 open-label, single-arm clinical trials, we measured the effect of BTKi's on de novo immune response against recombinant hepatitis B vaccine (HepB-CpG) and recall response against recombinant zoster vaccine (RZV) in CLL patients who were TN or on BTKi. The primary end point was serologic response to HepB-CpG (anti-hepatitis B surface antibodies \u226510 mIU\/mL) and RZV (\u2265fourfold increase in anti-glycoprotein E). The response rate to HepB-CpG was lower in patients on BTKi (3.8%; 95% confidence interval [CI], 0.7-18.9) than patients who were TN (28.1%; 95% CI, 15.6-45.4; P = .017). In contrast, the response rate to RZV did not differ significantly between the BTKi (41.5%; 95% CI, 27.8-56.6) and TN cohorts (59.1%; 95% CI, 38.7-76.7; P = .2). BTKi's were associated with a decreased de novo immune response following HepB-CpG, whereas recall immune response following RZV was not significantly affected by BTKi therapy. These trials were registered at www.clinicaltrials.gov as #NCT03685708 (Hep-CpG) and #NCT03702231 (RZV).<\/jats:p>","DOI":"10.1182\/blood.2020008758","type":"journal-article","created":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T16:39:05Z","timestamp":1606840745000},"page":"185-189","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":128,"title":["Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines"],"prefix":"10.1182","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9569-9605","authenticated-orcid":false,"given":"Christopher","family":"Pleyer","sequence":"first","affiliation":[{"name":"Hematology Branch, National Heart, Lung, and Blood Institute,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mir A.","family":"Ali","sequence":"additional","affiliation":[{"name":"Medical Virology Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey I.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Medical Virology Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1896-2462","authenticated-orcid":false,"given":"Xin","family":"Tian","sequence":"additional","affiliation":[{"name":"Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Soto","sequence":"additional","affiliation":[{"name":"Hematology Branch, National Heart, Lung, and Blood Institute,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inhye E.","family":"Ahn","sequence":"additional","affiliation":[{"name":"Hematology Branch, National Heart, Lung, and Blood Institute,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika M.","family":"Gaglione","sequence":"additional","affiliation":[{"name":"Hematology Branch, National Heart, Lung, and Blood Institute,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Nierman","sequence":"additional","affiliation":[{"name":"Hematology Branch, National Heart, Lung, and Blood Institute,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald E.","family":"Marti","sequence":"additional","affiliation":[{"name":"Hematology Branch, National Heart, Lung, and Blood Institute,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Hesdorffer","sequence":"additional","affiliation":[{"name":"Hematology Branch, National Heart, Lung, and Blood Institute,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Lotter","sequence":"additional","affiliation":[{"name":"Hematology Branch, National Heart, Lung, and Blood Institute,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanine","family":"Superata","sequence":"additional","affiliation":[{"name":"Hematology Branch, National Heart, Lung, and Blood Institute,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Wiestner","sequence":"additional","affiliation":[{"name":"Hematology Branch, National Heart, Lung, and Blood Institute,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8498-4729","authenticated-orcid":false,"given":"Clare","family":"Sun","sequence":"additional","affiliation":[{"name":"Hematology Branch, National Heart, Lung, and Blood Institute,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2021011416210460200_B1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.blre.2018.03.004","article-title":"Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections","volume":"32","author":"Hilal","year":"2018","journal-title":"Blood Rev"},{"issue":"7","key":"2021011416210460200_B2","first-page":"440","article-title":"Room for improvement: immunizations for patients with monoclonal B-cell lymphocytosis or chronic lymphocytic leukemia","volume":"12","author":"Whitaker","year":"2014","journal-title":"Clin Adv Hematol Oncol"},{"issue":"1","key":"2021011416210460200_B3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1182\/blood.2019003715","article-title":"Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib","volume":"136","author":"Sun","year":"2020","journal-title":"Blood"},{"issue":"21","key":"2021011416210460200_B4","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1182\/blood-2017-12-820910","article-title":"Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study","volume":"131","author":"Ahn","year":"2018","journal-title":"Blood"},{"issue":"12","key":"2021011416210460200_B5","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1001\/jamaoncol.2016.2437","article-title":"Seasonal influenza vaccination in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"2","author":"Sun","year":"2016","journal-title":"JAMA Oncol"},{"issue":"10","key":"2021011416210460200_B6","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.3324\/haematol.2017.164285","article-title":"Ibrutinib may impair serological responses to influenza vaccination","volume":"102","author":"Douglas","year":"2017","journal-title":"Haematologica"},{"issue":"23","key":"2021011416210460200_B7","doi-asserted-by":"crossref","first-page":"9047","DOI":"10.1073\/pnas.1118979109","article-title":"Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells","volume":"109","author":"Li","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7798","key":"2021011416210460200_B8","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"issue":"9","key":"2021011416210460200_B9","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1128\/CVI.00250-14","article-title":"Detection of antibodies to varicella-zoster virus in recipients of the varicella vaccine by using a luciferase immunoprecipitation system assay","volume":"21","author":"Cohen","year":"2014","journal-title":"Clin Vaccine Immunol"},{"issue":"5","key":"2021011416210460200_B10","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.vaccine.2017.12.038","article-title":"Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults","volume":"36","author":"Jackson","year":"2018","journal-title":"Vaccine"},{"issue":"11","key":"2021011416210460200_B11","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/infdis\/jiy095","article-title":"Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 years or older","volume":"217","author":"Cunningham","year":"2018","journal-title":"J Infect Dis"},{"issue":"22","key":"2021011416210460200_B12","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"issue":"13-14","key":"2021011416210460200_B13","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/S0264-410X(00)00409-6","article-title":"Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia","volume":"19","author":"Hartkamp","year":"2001","journal-title":"Vaccine"},{"issue":"25","key":"2021011416210460200_B14","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1016\/j.vaccine.2018.05.012","article-title":"Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group","volume":"36","author":"Svensson","year":"2018","journal-title":"Vaccine"},{"key":"2021011416210460200_B15","article-title":"Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL) [published online ahead of print 16 June 2020]","author":"Mauro","journal-title":"Leukemia"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/2\/185\/1797221\/bloodbld2020008758.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/2\/185\/1797221\/bloodbld2020008758.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T11:32:03Z","timestamp":1610623923000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/137\/2\/185\/474376\/Effect-of-Bruton-tyrosine-kinase-inhibitor-on"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,14]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,1,14]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020008758","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,14]]}}}